Friday, 21 January 2022



LATEST NEWS Chief Minister Jai Ram Thakur inaugurates Tax Haat Programme Sabreena Yaseen, a 16 year old athelete, releases her debut book "Fearless Flower" Congress Manifesto will address the expectations of all sections of society: Partap Singh Bajwa ‘Channi Govt Had Clearly Stage-Managed Blockade That Led To Pm’s Security Breach’ : Captain Amarinder Singh Punjab Police Seize Grenade Launcher, 3.79kg Rdx To Avert Terror Attack Around Republic Day; One Arrested Government of H.P and Haryana signs MoU for construction of Adi Badri Dam WHO warns Covid pandemic not over amid Europe case records Australian Open: Monfils continues dream run, Medvedev overcomes Kyrgios loses $34 mn in hack involving 483 users 'Jai Bhim', 'Marakkar' make it to Oscars 'submission list' When Badshah paid off loan for Rajasthan's 'Ismail Langha' group After his father Mammootty, Dulquer Salmaan tests Covid positive New webseries to binge watch this weekend An Action Hero' is mounted on a scale that deserves to be shot in big locations : Ayushmann Khurrana Decision to be taken on scientific basis: Karnataka Chief Minister on lifting of weekend, night curfew 'Godzilla and the Titans' live-action series in development Elon Musk's brain implant company 'Neuralink' nears human trials Army recovers over 30 kg narcotics along LoC in J&K's Poonch U-19 CWC: Mondol, Meherob bowl Bangladesh to big win over Canada U-19 CWC: Prest slams unbeaten 154 as England score massive win against UAE IANS Review: 'Breaking Point Season 2': Showcases the making of fearsome soldiers


Vaccinating 130Cr people with injectable Covaxin a challenge: Bharat Biotech

Web Admin

Web Admin

5 Dariya News

Hyderabad , 16 Nov 2020

Even as India's first indigenous coronavirus vaccine Covaxin is entering its third phase of human trials, Bharat Biotech on Monday raised the logistical query on "how to vaccinate 1.3 billion (130 crore) people with two injectable doses. Terming the exercise a "challenge" it also said that work was on single-dose nasal drop vaccine.Bharat Biotech International Limited (BBIL) Chairman and Managing Director Krishna Ella said the company's Bio-Safety Level 3 (BSL-3) facility currently has limited capacity but hoped to reach one billion (100 crore) doses by next year."We have partnered with ICMR (Indian Council of Medical Research) for Covaxin and as we speak, we are entering phase III trials but I am not happy because it is a two-dose injectable vaccine. If we have to vaccinate 1.3 billion population with two dose vaccine, we need 2.6 billion (260 crore) syringes and needles," he said.Ella was addressing Deccan Dialogue organised by the Indian School of Business (ISB) and supported by the Ministry of External Affairs (MEA) on 'Crisis and cooperation: Imperative in the times of pandemic'."We are working on another vaccine, a single dose nasal drop. We have experience of making Rotavirus and Polio nasal drop vaccines. We can scale up to 1 billion doses and my feeling is that by next year we will reach there," he said.The Hyderabad-headquartered vaccine maker announced in September that it is collaborating with the Washington University School of Medicine in St Louis, Missouri to manufacture a billion doses of a single-dose intranasal vaccine."The challenge is to vaccinate 1.3 billion population. Six billion (600 crore) people in the developing world have to be vaccinated but the opportunity is if 20 per cent of them are vaccinated, I have done my job as a scientist. You partly need vaccine because there will be herd immunity," he added.Ella also pointed out that 40,000 unknown viruses are existing. "10,000 viruses can hop from animal to animal and to human. What we are seeing today is only a sample. Because of its impact on economy it got more attention. We are yet to see lot many things."Indian Institute of Technology (IIT), Hyderabad's Prof M. Vidyasagar, who is also the chairman of the 'COVID-19 Indian National Supermodel Committee', however, said for this pandemic 30 to 40 per cent people needed to be vaccinated to achieve herd immunity."The challenge is whether the cold weather especially in north India exacerbate this pandemic and whether we can predict this by observing the course of the pandemic," he said.He noted that India had more success in controlling the pandemic unlike other countries like the US, the UK and France who have death rate per million 7 to 8 times higher than that of India."These countries have gone back to second lockdown because they see so-called second wave. This raises the question could proper modeling have helped these countries to foresee that there will be second wave, whether it could have helped the countries to assess effectiveness of the first lockdown, would the second lockdown be more effective this time when it was apparently not successful the last time," said Prof Vidyasagar.Arti Ahuja, Additional Secretary, Ministry of Health and Family Welfare, said India should be proud of what it has done to deal with the pandemic.She said from just one public health institute conducting COVID-19 test, the country now has 2,000 laboratories. According to her, it was not just the government but the participation of all stakeholders, including the private sector which helped the country deal with the pandemic.Rahul Chabra, Secretary, Economic Relations, Ministry of External Affairs, said the pandemic brought out new aspects of non-military threats to the security. Health security came up as major issue and multilateral cooperation now has to be part of strategic foreign policy engagement with all countries.Vikram K. Doraiswamy, India's High Commissioner to Bangladesh, Prof Sarang Deo, Executive Director, Max Institute of Healthcare Management, ISB also addressed the session, which was moderated by Govindraj Ethiraj, Founder, IndiaSpend and BOOM.


Tags: Coronavirus , COVID 19 , Novel Coronavirus , Fight Against Corona , Corona Virus Updates , Social Distancing , Coronavirus Epidemic , Coronavirus Pandemic , Corona virus threat , Corona Outbreak , Covid-19 pandemic , Hyderabad , Bharat Biotech , Bharat Biotech International Limited , BBIL , Krishna Ella , Covaxin , Covid-19 vaccine



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD